Alto Neuroscience (ANRO) Cash & Equivalents (2023 - 2026)

Alto Neuroscience has disclosed Cash & Equivalents across 4 years of filings, most recently posting $263.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $263.8 million, up 64.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $263.8 million (up 64.08% YoY), and the FY2025 annual result was $176.5 million, up 4.93% from the prior year.
• Cash & Equivalents came in at $263.8 million for Q1 2026 at Alto Neuroscience, up from $176.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $263.8 million in Q1 2026 to a low of $82.5 million in Q4 2023.
• The 4-year median for Cash & Equivalents is $172.3 million (2024), against an average of $171.8 million.
• Across the five-year window, Cash & Equivalents surged 103.88% in 2024 and fell 24.15% in 2025, its largest moves.
• Alto Neuroscience's Cash & Equivalents stood at $82.5 million in 2023, then soared by 103.88% to $168.2 million in 2024, then gained by 4.93% to $176.5 million in 2025, then jumped by 49.45% to $263.8 million in 2026.
• The last three Cash & Equivalents figures came in at $263.8 million (Q1 2026), $176.5 million (Q4 2025), and $137.8 million (Q3 2025), per Business Quant data.